‘Shocked, stunned, and saddened': Illinois officials react to Health Alliance discontinuing plans
Health Alliance discontinuing plans at year's end; Medicare Advantage to continue
State Senator Paul Faraci (D-Champaign) said this decision will leave thousands in a critical position.
'I am deeply concerned and disappointed by Health Alliance's recent decision to end health care coverage for many of its members. The impact of this is far-reaching, as it places thousands of people at risk of losing critical health coverage. I urge Health Alliance, which has been a long-trusted provider for families across our communities, to protect their members, rather than leaving them with uncertainty surrounding the care they need,' Faraci said.
Faraci also added in his statement that he will work to help find a solution for those impacted.
We must work together to ensure the thousands of impacted individuals, including 600 Health Alliance employees, are not left vulnerable. I stand ready to support a solution that keeps our constituents' health and well-being at the forefront.
State Senator Paul Faraci
Insurance expert breaks down implications of Health Alliance's discontinued services
State Senator Chapin Rose (R-Mahomet) said he is 'shocked, stunned, and saddened,' to learn that Health Alliance will cease operations by 2026.
'The affected employees, their families, and the tens of thousands of local insureds who rely on Health Alliance for access to care are foremost on my mind. My office will stand by to try and help in any way we can in job training and recruitment efforts for the impacted employees,' Rose said.
In his statement, Rose added that he is already working to find new options for Health Alliance customers.
Moreover, I have already reached out to the state's CMS Director, who is in charge of the group health insurance contract under Gov. Pritzker, to see what healthcare options will be available come open enrollment in May for the countless families who currently utilize Health Alliance for their insurance provider. Continuity of care and access to trusted physicians must be the priority as thousands of local members will now be forced to find a new insurance carrier. Being able to choose your medical care team going forward is an absolute imperative.
State Senator Chapin Rose
Horizon Health expanding to Tilton
Senator Chris Balkema (R- Channahon) is based in Will County. He assured constituents there are resources available to them at this time.
My heart goes out to the families and employees impacted by this difficult news. Losing a trusted healthcare provider creates uncertainty and stress, and I want everyone affected to know they are not alone. To the employees facing job loss, we will do everything we can to connect you with resources and new opportunities. I am committed to working with state and local partners to ensure families have the information and support they need to navigate this transition.
Senator Chris Balkema
Balkema added that his office is available to answer any questions or concerns.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
6 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
Business Insider
8 hours ago
- Business Insider
With UnitedHealth Group (UNH) Stock Down Over 50%, Let's Look at Who Owns It
UnitedHealth Group (UNH) has had a rough ride in 2025. The stock is down over 56% year-to-date, hit by rising medical costs, a DOJ probe, executive changes, and now disappointing Q2 results. The company recently posted adjusted earnings per share of $4.08 on $111.6 billion in revenue, narrowly beating the revenue forecast but missing the EPS consensus of around $4.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Still, the company reaffirmed its full-year guidance and provided more clarity on its 2025–2026 outlook, prompting mixed reactions from analysts. For instance, analyst Lance Wilkes from Bernstein remains optimistic, citing UnitedHealth's strong market position and potential rebound in Medicare Advantage trends. In contrast, BofA analyst Kevin Fischbeck is more cautious, due to concerns over the company's slower growth pace. With the stock in focus, now's a good time to take a closer look at who actually owns UNH shares. Now, according to TipRanks' ownership page, public companies and individual investors own 45.60% of UNH. They are followed by mutual funds, ETFs, other institutional investors, and insiders at 28.84%, 23.20%, 2.19%, and 0.18%, respectively. Digging Deeper into UnitedHealth Group's Ownership Structure Looking closely at top shareholders, Vanguard owns the highest stake in UNH at 8.89%. Next up is Vanguard Index Funds, which holds a 7.03% stake in the company. Among the top ETF holders, the Vanguard Total Stock Market ETF (VTI) owns a 3.22% stake in UNH stock, followed by the Vanguard S&P 500 ETF (VOO), with a 2.84% stake. Moving to mutual funds, Vanguard Index Funds holds about 7.03% of UNH. Meanwhile, Fidelity Concord Street Trust owns 1.72% of the company. Is UNH a Good Buy Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, three Holds, and two Sells assigned in the last three months. At $321.76, the average UnitedHealth stock price target implies a 28.93% upside potential.
Yahoo
19 hours ago
- Yahoo
An Unpopular Pick: 5 Reasons Why Buying UnitedHealth Group Stock Now Could Be a Brilliant Move
Key Points UnitedHealth Group continues to face multiple challenges. The company has a plan to address the issues and boost its bottom line. The stock is a bargain with solid long-term growth prospects. 10 stocks we like better than UnitedHealth Group › An old country song morbidly titled "Gloom, Despair, and Agony on Me" included the lyrics, "If it weren't for bad luck, I'd have no luck at all." This might be an apt motto for UnitedHealth Group (NYSE: UNH) these days. The healthcare giant continued to disappoint investors with its 2025 second-quarter update, revealing that full-year earnings will be worse than expected. The U.S. Department of Justice (DOJ) is conducting an investigation of UnitedHealth related to its Medicare billing practices, and its share price has plunged nearly 60% from the peak set in late 2024. UnitedHealth Group stock is a decidedly unpopular pick. However, here are five reasons why buying this beaten-down stock could be a brilliant move. 1. The company has a plan to address its problems It would be one thing if UnitedHealth Group's challenges were insurmountable, but they're not. The company has a clear and compelling plan to address its problems. UnitedHealth didn't anticipate how hard it would be hit by rising medical costs, especially with its Medicare Advantage plans. The most effective solution to this issue is simple: Raise premiums. That's exactly what UnitedHealth plans to do, but it has to wait until the beginning of next year for most premium hikes to take effect. Since commercial plans renew throughout the year, the company can implement premium changes more quickly with this line of business. Tim Noel, the new CEO of the UnitedHealthcare insurance business, said in the Q2 earnings call that his unit will have "strongly responsive pricing for 2026." That's not the only step the company is taking, though. Noel stated that UnitedHealthcare has "stepped up our audit clinical policy and payment integrity tools to protect customers and patients from unnecessary costs." He added that the business is also streamlining its provider networks, especially for Medicare Advantage plans. UnitedHealth Group's Optum segment isn't performing as well as desired, either. Again, though, the company is implementing a plan to fix the problems. Optum CEO Patrick Conway said in the Q2 call that price increases are coming to reflect high patient acuity and risk. He also mentioned that Optum Health will discontinue serving around 200,000 patients. 2. Cost-cutting should boost the bottom line UnitedHealth Group is also moving forward with cost-cutting initiatives to boost its bottom line. CEO Stephen Hemsley referred to "meaningful cost opportunities within the enterprise" in his comments during the Q2 call, adding, "[W]e are pursuing them with urgency." Noel highlighted his unit's efforts to scale artificial intelligence (AI) across health plan operations, which should generate cost savings while improving patient and provider experiences. Conway expects Optum Health to deliver nearly $1 billion in cost savings in 2026. 3. Long-term growth prospects remain strong Despite UnitedHealth's challenges over the near term, its long-term growth prospects remain strong. The company expects to return to earnings growth next year. Hemsley predicts that earnings growth will accelerate in 2027 and beyond. Is this upbeat assessment merely the result of a CEO looking through rose-colored glasses? I don't think so. The consensus among analysts surveyed by LSEG is that UnitedHealth Group will deliver solid year-over-year earnings growth in 2026. 4. An experienced, steady hand is now at the wheel It's also important for investors to remember that UnitedHealth Group once again has an experienced, steady hand at the wheel. Hemsley returned to run the company two months ago. He previously served as CEO from 2006 to 2017, a period during which UnitedHealth Group flourished and its share price soared. 5. The stock is a bargain Last, but not least, UnitedHealth Group stock is a bargain. Its shares trade at a forward price-to-earnings ratio of below 11.6. That's not much higher than the valuation during the financial crisis of 2008 and 2009. Does the DOJ investigation justify such a low earnings multiple? I don't think so. UnitedHealth survived a previous lengthy investigation, with a court-appointed Special Master ultimately concluding that there wasn't evidence that the company had done anything wrong. Independent audits from the Centers for Medicare and Medicaid Services show that UnitedHealth's Medicare practices are, in the company's words, "among the most accurate in the industry." UnitedHealth Group insists that it "has full confidence in its practices." Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. An Unpopular Pick: 5 Reasons Why Buying UnitedHealth Group Stock Now Could Be a Brilliant Move was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
